Your browser doesn't support javascript.
loading
Ramucirumab in HER-2-positive gastroesophageal adenocarcinoma: an argument for overcoming trastuzumab resistance.
Tehfe, Mustapha; Tabchi, Samer; Laterza, Maria Maddalena; De Vita, Ferdinando.
Afiliação
  • Tehfe M; Department of Medical Oncology, Centre Hospitalier de l'Université de Montréal, Montréal, QC H2L 4M1, Canada.
  • Tabchi S; Department of Medical Oncology, Centre Hospitalier de l'Université de Montréal, Montréal, QC H2L 4M1, Canada.
  • Laterza MM; Department of Medical Oncology, University of Naples 'Luigi Vanvitelli', NA 80138, Italy.
  • De Vita F; Department of Medical Oncology, University of Naples 'Luigi Vanvitelli', NA 80138, Italy.
Future Oncol ; 14(3): 223-228, 2018 02.
Article em En | MEDLINE | ID: mdl-29318901
ABSTRACT

AIM:

Patients with advanced gastric cancer have a relatively poor prognosis with few therapeutic alternatives beyond first-line therapy. The purpose of this manuscript is to highlight the potential for prolonged responses in patients with HER-2-positive disease. Patients, materials &

methods:

We analyzed the data of patients diagnosed with HER-2-positive-advanced gastric cancer who progressed on trastuzumab-based combination therapy and subsequently received second-line therapy consisting of ramucirumab in combination with paclitaxel.

RESULTS:

Most patients had a stable disease after ramucirumab-based therapy (50%, 5/10), median duration to disease control was 8 months.

CONCLUSION:

The prolonged duration of response that we observed indicates that an interaction between the EGF pathway and the angiogenesis pathway requires further clinical investigations.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Neoplasias Esofágicas / Adenocarcinoma / Junção Esofagogástrica / Antineoplásicos Imunológicos / Anticorpos Monoclonais Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Future Oncol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Canadá

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Neoplasias Esofágicas / Adenocarcinoma / Junção Esofagogástrica / Antineoplásicos Imunológicos / Anticorpos Monoclonais Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Future Oncol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Canadá